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Abstract 
Background. Our studies on the role of cholesterol in prion infection/replication showed that 
brains and peripheral cells of sheep susceptible to or suffering from Scrapie were 25 
characterized by an altered cholesterol homeostasis compared to animals with a scrapie-
resistant genotype, and that drugs influencing cholesterol esterification were endowed with 
selective anti-prion activity in N2a cell lines infected with the 22L and RML prion strains.  
Results. In prion-infected N2a cell lines we now report increased anti-prion activity of dual-
drug combinations consisting of cholesterol ester modulators associated with prion inhibitors 30 
Synergism was obtained with the cholesterol ester modulators everolimus, pioglitazone, 
progesterone, and verapamil associated with the anti-prion chlorpromazine, and with 
everolimus and pioglitazone associated with the anti-prion quinacrine. Comparative lipid 
analyses in prion-infected and non-infected N2a cells by colorimetric, enzymatic, and 
chemical means, clearly demonstrated a derangement of type and distribution of cholesterol 35 
esters, free cholesterol, and triglycerides in the infected N2a cells. Although single-drug 
treatments influenced lipid syntheses, only the combined-drug treatments appeared to restore 
a lipid profile similar to that of untreated-uninfected cells.  
Conclusions. We conclude that the anti-prion synergistic effect of cholesterol ester 
modulators with the cholesterol metabolism interfering anti-prion drugs chlorpromazine and 40 
quinacrine may arise from the ability of combined drugs to re-establish the intracellular lipid 
profile of untreated-uninfected cells. Overall, these data suggest that inhibition of prion 
replication can be readily potentiated by combinatorial drug treatments, and that steps of 
cholesterol/cholesterol ester metabolism may represent suitable targets. 
 45 
Abbreviations: Total lipids, (TL), neutral lipids (NL), total cholesterol (TC), cholesterol esters 
(CE), free cholesterol (FC), triglycerides (TG),  phospholipids (PL), dextran sulphate 500,000 
(DX 500), tannic acid (TA), chlorpromazine (CP), quinacrine (Q), everolimus (EVE), 
pioglitazone (PIO), progesterone (PG), verapamil (VP).  
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Introduction 
Prions are unconventional infectious agents involved in fatal neurodegenerative diseases of 
mammals [1]. Prion replication involves conversion of cellular prion protein isoforms, named 
PrP
C
, into disease-specific isoforms, designated PrP
Sc
. Several compounds have been 
identified in prion-cell systems as inhibitors of the PK-resistant prion protein (PrP
res
), and 5 
some of them have shown a protective effect in rodent prion models [2-4].  
Based on the concept that combinatory strategies might prove more effective than 
monotherapy, Kocisko et al. [5] found, using combinations of intraventricular pentosan 
polysulphate (PPS) and porphyrin FeTSP, enhanced anti-scrapie effect in mice. In humans, 
single intraventricular PPS treatment was reported to increase the mean survival of seven 10 
prion-diseased individuals [6]. However, due to the lack of formal drug evaluation in 
controlled randomized studies in humans, it is not yet possible to draw any conclusion
 
on the 
real effectiveness of PPS or that of several other agents tested [7]. The results of two ongoing 
clinical trials evaluating quinacrine in the USA (CJD quinacrine study, NCT 00183092) and
 
in the UK (NCT 00104663,
 
ISRCTN 06722585) are as yet unpublished.  15 
Apart from comparative controlled studies on available drugs, efforts are being made to 
identify more successful therapeutic approaches, as well as novel molecular targets and 
inhibitors. In this context, our studies on the role of cholesterol in cell susceptibility to prion 
infection/replication showed that brains and peripheral cells (i.e. skin fibroblasts and blood 
monuclear cells) of sheep suffering from Scrapie displayed altered cholesterol homeostasis, 20 
with abnormal accumulation of cholesterol esters (CE), and altered expression of genes and 
gene products involved in cholesterol metabolism/trafficking [8-10]. In addition, we showed 
that drugs able to reduce CE content, i.e. everolimus, pioglitazone, Sandoz 58035, 
progesterone, and verapamil, were also able to inhibit PrP
res
 formation in persistently prion-
infected N2a cells [11].  25 
We report here enhanced anti-prion effect of selected prion inhibitors in dual-drug 
combinations with everolimus, pioglitazone, progesterone, and verapamil. Quinacrine and 
chlorpromazine were used as anti-prion agents known to prevent PrP
res
 formation in the 
endocytic compartment [12], whereas dextran sulphate 500,000 (DX500) and tannic acid 
(TA) were used as inhibitors acting on PrP
res
 formation at the plasma membrane site. Like 30 
PPS, DX500 is a sulphated polyanion which is thought to bind to PrP
C
 or PrP
res 
[13,14], 
whereas polyphenol tannic acid is known to stabilize plasma-membrane saturated 
phosphatidyl choline residues, thereby affecting PrP
C
 to PrP
res
 conversion [15].  
 
Experimental procedure 35 
Chemicals. Dextran sulphate sodium salt (MW 500 000), verapamil (VP) hydrochloride 
(98%), chlorpromazine (CP) hydrochloride, quinacrine (Q) dihydrochloride, and progesterone 
(PG), were purchased from Sigma-Aldrich (Italy). Tannic acid (TA) was purchased from MP 
Biomedicals (USA). Everolimus (EVE) was provided by Novartis (Switzerland), and 
pioglitazone (PIO) by Takeda (Japan). DX 500 was solubilised in OptiMEM, and stored at -40 
20°C. EVE was solubilised in 100% ethanol and stored at +4°C. PIO was solubilised in 100% 
ethanol and stored at room temperature. Stock solutions of the other compounds were 
prepared in DMSO and stored at -20°C.  
Cell lines and PrP
 
analysis. Mouse neuroblastoma N2a cell line and sublines persistently 
infected with the 22L and RML strains of mouse-adapted scrapie (22L-N2a, RML-N2a), were 45 
a generous gift by Byron Caughey, NIH/NIAID Rocky Mountain Laboratories, USA. Cells 
were grown at 37°C, 5% CO2, in OptiMEM supplemented with 10% FBS (Gibco, Invitrogen; 
Italy), 2mM L-glutamine, 50 U/ml penicillin G sodium and 50 µg/ml streptomycin sulphate 
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(Gibco, Invitrogen; Italy), and split every 3 to 4 days. Cell lines were stored in liquid nitrogen 
and working cultures were replaced every two-three months. All experiments were carried out 
in exponentially growing cells or sub-confluent cultures. PrP
C
 and PK-resistant PrP (PrP
res
) 
were detected in cell lysates by dot blot procedure with the mouse anti-PrP antibody 6H4 
(Prionics, Zurich; 1:5.000) as previously described [11].  5 
Effect of single vs. dual drug treatments on PrP
res
 formation. Approximately 5.000 of prion-
infected N2a
 
cells in 90 µl of growth medium were added to each well of a Microtest flat-
bottom 96-well plate with a low-evaporation lid (Becton Dickinson, USA). The cells were 
allowed to settle overnight before addition of 10 µl (10x solutions) of different concentrations 
of the drugs. For dual drug combinations, cell cultures were treated with 5 µl (20x solutions) 10 
of serial drug dilutions (serial ½ fractions) of each compound. Cells were either exposed to 
both drugs at the same time or pre-treated for 8 hours with one inhibitor before addition of the 
second one. DMSO in the cell medium was never higher than 0.2% (v/v). Each drug 
combination was tested in duplicate and each experiment was performed at least twice. After 
96-hour incubation at 37°C in 5%CO2, cells were processed for PrP
res
 detection. 15 
Autoradiography films of PrP
res
 blots were captured in TIFF format and intensity of each dot 
was determined through the Scion Image software (NIH). The mean value of PrP
res
 at each 
drug concentration and at each drug combination was expressed as a percentage of control 
cultures (i.e. untreated and single-drug treated cultures, respectively). EC50 values (50% 
inhibition) were determined by linear regression analysis. Duplicate cultures were drug treated as 20 
above and after 96 hours processed for evaluation of cell viability at each drug 
concentration/combination with the MTT method as described [11].  
Type of interaction of dual drug treatments on PrP
res
 formation. The results of dual drug 
treatments on the generation of PrP
res
 were plotted according to the isobole method [16], a 
well-known procedure for the evaluation of synergism, additivity, indifference, or antagonism 25 
which requires experimental data for the agent used alone and in different dose combinations 
at equal-effective levels (fractions of EC50s). According to this procedure, a combination is 
said to show zero interaction (i.e. additive) if the data points are on the straight line 
connecting the EC50 of the single agents; the points below this line correspond to synergistic 
interactions; those above the line indicate indifference and antagonism. To measure the degree 30 
of drugs interaction, FIC index was calculated according to the equation: FIC = (EC50A
comb
/ 
EC50A
alone
) + (EC50B
comb
/ EC50B
alone
). By this method, interactions are considered synergistic 
if the FIC index is <1, additive to indifferent if the FIC index is comprised between 1 and 2, 
and antagonistic if the FIC index is >2. The reduction in the EC50s of the anti-prion drugs 
when they were given in combination compared to the EC50s when given alone, were 35 
compared through a paired rank test, a non parametric test for comparison between two 
related samples. A p value < 0.05 was considered significant. 
Evaluation of drug efflux activity. Drug efflux activity of P-gp protein was determined by 
measuring intracellular accumulation of radioactive vinblastine as previously described [17]. In 
brief, 22L-N2a cells were seeded at 1x10
4
 cells/ml in growth medium (OptiMEM supplemented 40 
with 10% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin) in a Microtest flat-bottom 24-
well plate with a low-evaporation lid (Becton Dickinson, USA). Cultures were allowed to 
settle overnight and then further incubated in the absence and in the presence of different 
concentrations of the cholesterol inhibitors. After 96 hours of incubation, cell cultures were 
washed twice with PBS and re-incubated at 37 °C in ½ final volume of fresh growth medium 45 
containing or not the drugs. One hour later, cells were re-fed with equal volume of identical pre-
warmed medium supplemented with 0.1 µCi/ml [G-
3
H]vinblastine sulfate (15.5 Ci/millomole; 
Amersham Life Sci.). After 1-hour pulse, cell monolayers were rapidly washed 3 times with ice-
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cold PBS, solubilized in 0.1N NaOH, and analyzed for protein and [G-
3
H]-vinblastine content in 
a Beckman β-Counter. The amount of intracellular [G-
3
H]-vinblastine is reported as CPM per µg 
of total cellular protein, as determined by the bicinchoninic acid (BCA) protein assay (Sigma-
Aldrich) [11]. Each determination was performed in triplicate. 
Intracellular lipid staining. To visualize intracellular lipids, N2a and 22L-N2a
 
cells were 5 
seeded at 1x10
4
/ml in growth medium in Microtest flat-bottom 24-well plates (Becton 
Dickinson, USA). After overnight settlement, 22L-N2a
 
cultures were drug-treated under 
conditions used for evaluation of anti-PrP
res
 activity. Each drug and drug combination was 
tested in triplicate. After 96-hour incubation, untreated and drug treated cultures were washed 
with PBS, fixed by soaking in 10% formalin and then stained with Oil red-O (ORO) (Sigma), 10 
Nile red (9-diethylamino-5H-benzo[α]phenoxazine-5-one, Fluka, Buchs, SG, Switzerland) 
and filipin (Sigma). ORO is a lipid-soluble dye which stains NL ( i.e. CE and TG), but not 
FC. ORO staining was performed in 60% isopropyl alcohol, followed by Mayer’s 
hematoxylin counterstaining for nuclei [11]. After staining, cells were imaged using a Leitz 
inverted-phase microscope fitted with a digital camera. NL appear as bright red spots in the 15 
cell cytoplasm. At least two different fields per sample were imaged and analyzed. Red ORO 
intensity was quantified by NIH Image J software utilizing four different selected regions of 
interest (ROIs), and values arbitrarily expressed as mean pixels± SE/cm
2
 of triplicate wells. 
Nile red is a fluorescent dye that stains differentially polar lipids (i.e. phospholipids, PL) and 
NL (i.e. CE and TG) [18]. PL show a prevalent red emission, while NL show both red and 20 
green emission. Red emission was observed with 540±12.5 excitation and 590 LP emission 
filters. Green emission was observed with 460±25 excitation and 535±20 emission filters. 
Filipin is a fluorescent dye which stains only FC (blue emission). Filipin was observed with 
360±20 excitation and 460±25 emission filters. Filipin and Nile red emissions were 
completely separated by the above indicated filters, so the two fluorochromes could be used 25 
in combination on the same cells [19]. Quantitative image analysis was performed with the 
ImagePro Plus package (Media Cybernetics, Silver Springs, MD). 
Cellular lipid content, synthesis, and efflux. For determinations of the different lipid 
subclasses in N2a and 22L-N2a cells, TL were extracted with cold acetone from a total of 
30x10
6 
of each cell line collected from sub-confluent flasks. Extracted lipids were split into 30 
two equal aliquots and air dried: one aliquot was used to determine TC by the cholesterol 
oxidase method (Sclavo Diagnostics, Siena, Italy); the other aliquot, after drying, was 
resuspended in 100 µl of chloroform and analysed for lipid subclasses by thin layer 
chromatography (TLC) on kiesegel plates using a solvent system containing n-
heptane/isopropyl ether/formic acid (60:40:2 v/v/v). Separated bands were identified as FC, 35 
CE, and TG by comparison with reference standards run simultaneously side-by-side and 
visualized under iodine vapors.  Bands were excised and their masses determined by the 
cholesterol oxidase (for FC and CE) and peroxidase (for TG) assay methods (Sclavo 
Diagnostics, Siena, Italy). To determine the effect of drugs and drug combinations on lipid 
synthesis and efflux, N2a and 22L-N2a
 
cells were seeded at 1x10
4
/ml in growth medium in 40 
Microtest flat-bottom 24-well plates (Becton Dickinson, USA). After overnight settlement, 
22L-N2a
 
cultures were drug-treated and incubated under the condition used for evaluation of 
anti-PrP
res
 activity. Each drug and drug combination was tested in triplicate. Six hours before 
harvesting, 5 µCi/ml sodium 14C-acetate (DuPont, NEN; specific radioactivity 50 mCi/mmol) 
were added to each well. At the end of labelling, TL in the cell monolayers and in the growth 45 
media were extracted with cold acetone and lipid subclasses separated by TLC as described 
above. The incorporation of 14C-acetate into lipid sub fractions was measured in a Liquid 
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Scintillation Counter. Efflux of 14C-TL was expressed as the percentage of the radioactivity 
recovered in medium/total radioactivity (cells + medium). 
Statistical analysis. Unless otherwise indicated, data are reported as mean ± standard error 
(SE). Statistical calculations were performed using the statistical analysis software Origin 8.0 
version (Microcal, Inc, Northampton, MA, USA). Data analysis was done using the Student t-5 
test. A value of p<0.05 was considered to be statistically significant. 
 
Results 
Anti-PrP
res
 activity of prion inhibitors in combination with CE modulators. 
The inhibitory effect of single vs. dual-drug treatments on PrP
res
 generation was evaluated in 10 
22L-infected cells by dot blot procedure [20], a method equally reliable but more suitable 
than Western blot-based assay for comparative studies of multiple drugs. 22L-N2a cell 
cultures were exposed to fractions of the EC50 (serial ½ drug dilutions) of each compound, 
alone and in association. Dual-drug treatments were either performed at the same time or in 
sequential order: 8 hrs treatment with one drug before adding the second drug. Type and 15 
degree of drug interactions were analyzed by both isobole and FIC index methods [16]. The 
effect of combined treatments ranged from synergism to indifference, depending on the prion 
inhibitor considered, drug concentration, and the temporal sequence of drug addition. 
Simultaneous treatments, as well as sequential combination with prion inhibitors which 
preceded CE modulators, always resulted in an additive or indifferent type of interaction (not 20 
shown).Sequential combinations comprising any CE modulator followed by DX500 or TA 
also resulted in an additive or indifferent type of interaction. Isoboles and FIC indices of 
combinations comprising EVE and PG followed by DX500 and TA are shown in Fig.1A. By 
contrast, a marked enhancement of the anti-prion effect was obtained when cells were treated 
with any CE modulator followed by CP. Pre-treatments with EVE, PIO, PG, or VP, resulted 25 
in anti-prion effects in the range of synergism, as indicated by either FIC values (0.21-0.73) or 
data points in isoboles (Fig.2A). Significant reduction of CP EC50 (10 to 1.8µM [p <0.01]), 
EVE (1 to 0.1µM [p <0.01]), PIO (40 to 5µM [p <0.05]), PG (35 to 5µM [p <0.05]), and VP 
(10 to 2.5µM [p<0.05]) was observed. Sequential combinations of CE modulators followed 
by Q resulted in different drug interactions, depending on the dose and type of CE modulator. 30 
Pre-treatments with low doses of EVE, PIO, and PG resulted in synergistic interactions (FIC 
values: 0.18-0.25, EVE; 0.29-0.5, PIO; 0.70-0.71, PG), while higher doses resulted in additive 
effects. VP showed additive interaction at any concentration (FICs 0.95-1.13) (Fig.3A). 
Significant reduction of Q EC50 (1 to 0.1µM [p <0.01]), EVE (1 to 0.08µM [p <0.01]), and 
PIO (40 to 5µM [p <0.05]) was observed. Representative dot blots after single and dual-drug 35 
combination treatments comprising EVE, DX500, CP, and Q are shown (Fig.1-3B). Notably, 
similar drug interactions against PrP
res
 formation were also obtained in N2a cells infected 
with the RML prion strain (data not shown). Anti-prion effects were not due to cytotoxicity, 
as neither single nor dual-drug treatments affected cell viability and proliferation at active 
concentrations (Table 1).  40 
 
Effect of CE modulators on P-gp drug efflux activity.  
In multidrug-resistant cell lines, PG and VP are known chemo-sensitizers of unrelated 
cytotoxic agents via the inhibition of membrane drug-efflux P-gp protein [21, refs therein]. To 
investigate whether synergism was due to increased CP and Q cell retention, the overall drug-45 
efflux potential of 22L-N2a cells was investigated. Cells were exposed to the CE modulators 
for either 1 hour (i.e. standard procedure for measuring drug-efflux P-gp activity) or 96 hours 
(i.e. our test condition to evaluate anti-prion activity), and then pulse-labelled with 
3
H-
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vinblastine, a known P-gp substrate [17,21]. VP and PG, at concentrations close to their EC50s 
(i.e. 10µM and 35µM, respectively), increased intracellular vinblastine content with respect to 
untreated cultures (Table 2). VP resulted a better P-gp inhibitor than PG and determined 
higher vinblastine influx after both short (1 hr) and prolonged (96 hrs) exposure to the drug. 
However, treatments with concentrations (i.e. 7.5µM and 2.5µM, respectively) closer to 5 
synergistic ones, had no effect on vinblastine retention. EVE showed negligible anti-P-gp 
activity following treatments with 1 µM and 0.5 µM, and had no effect at a dose (0.05 µM) 
higher than that showing the strongest anti-prion synergism in combination with both CP and 
Q. Intriguingly, a high dose of PIO (40 µM), while not affecting vinblastine influx after short 
treatment, determined a marked retention of labelled vinblastine after prolonged treatment.  10 
 
Effect of single vs. dual-drug combinations on intracellular lipids.  
Given that it was unlikely that observed synergisms were due to intracellular retention of anti-
prion drugs, we investigated whether the combined drugs interacted at the level of lipid 
metabolism. The effect on intracellular lipids of a drug combination with marked anti-PrP
res 
15 
synergism, such as EVE (0.02 µM) and CP (2 µM), was initially determined by staining cells 
with dyes with affinity for different lipids (ORO, NL; Nile red, NL and PL; filipin, FC). As 
expected [11], ORO staining revealed significantly higher NL in the 22L-N2a compared to 
uninfected N2a cells (Fig.4A and B). However, both single and combined drug treatments 
markedly reduced red ORO intensity in the 22L-infected cell line. More detailed information 20 
was obtained with Nile red, a fluorescent hydrophobic probe that, being based on the different 
sensitivity of red and green emissions to low- and high-hydrophobic lipids, respectively, 
allowed us to distinguish neutral from polar (i.e. membrane PL) lipids. Combined staining 
with Nile red and filipin, a fluorescent sterol binding agent, allowed us to also co-localize FC 
(blue emission). With respect to uninfected cells, 22L-infected cultures showed an increase in 25 
both polar and neutral lipids, as well as in FC (Fig. 5A and B). In agreement with ORO data, 
22L-N2a cells showed a higher green emission signal - indicative of higher NL content. 
However, in the cytoplasm most of the green Nile-red staining was spread, rather than being 
localized in large lipid droplets. 22L-N2a cells showed also a more intense filipin 
fluorescence - indicative of a higher FC content, some of which was spread in the cytoplasm. 30 
Single treatment of infected cultures with EVE determined a marked reduction of all forms of 
intracellular lipids, whereas treatment with CP had a lower, although significant, effect on 
both PL and CE, but no significant effect on FC. Interestingly, combined EVE and CP 
treatments of infected cells appeared to re-establish the intracellular lipid profile of untreated-
uninfected cells. 35 
 
Lipid content in N2a vs. 22L-N2a by TLC. 
The above data clearly indicate that 22L-infected cells displayed higher NL compared to 
uninfected cells. However, there was a marked difference in dye intensity values between  
ORO and Nile red staining: compared to N2a, 22L-N2a cells showed over 5-fold-higher ORO 40 
stain and only approximately 1.5-fold-higher green Nile-red fluorescence. This discrepancy 
led us to more accurately determine the lipid content in N2a and 22L-N2a cell extracts. As 
seen in Figure 6 (A and B), the cholesterol oxidase assay revealed a TC content 1.7-fold 
higher in infected cells. TLC separation of lipid subclasses showed that 22L-N2a cells had 
higher levels of both FC (1.6-fold) and CE (5.5-fold) than N2a cultures, with 3.1 and 10.3 45 
FC/CE ratios, respectively. Extracts of infected cells had also 1.9-fold higher levels of TG. 
Lipid determination by enzymatic and chemical means confirmed, even though not in a 
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stoichiometric manner, that infected cells display a higher level of all lipid sub-fractions, and 
additionally identified CE as the most altered of all lipid subclasses.  
 
Effect of single vs. dual-drug combinations on lipid synthesis and efflux in 22L-N2a.  
To draw more consistent conclusions regarding the effects of drugs and drug combinations on 5 
cellular lipid homeostasis, we compared lipid neosynthesis (FC, CE, TG) and lipid efflux 
(mainly FC) in N2a vs. 22L-infected N2a cells, either untreated or treated with single and 
dual-drug combinations of EVE (0.02 µM), CP (2 µM), and Q (0.2 µM). Once again, 
14
C-
acetate incorporated into TL was higher in the 22L-N2a than in N2a cells (Fig.7A). In spite of 
a slight increase in TL efflux in the 22L-infected cultures, the percentage of TL efflux did not 10 
significantly differ between the two cell lines. TLC separation of lipid subclasses showed that 
the higher lipid syntheses in the 22L-N2a cells was due to increased neosynthesis of FC (1.5-
fold), CE (2-fold), and TG (1.6-fold) (Fig.7B). In 22L-N2a cells, both single and combined 
drug treatments greatly affected all lipid syntheses. However, single-drug treatments 
differently affected the synthesis of each individual lipid type, whereas combined drugs 15 
appeared to restore all lipid syntheses to the levels observed in untreated-uninfected cells 
(Fig.7A and B).  
 
Discussion 
Drugs targeting steps of cholesterol metabolism/esterification were found by us to enhance 20 
the anti-prion activity of chlorpromazine and quinacrine, by reducing their EC50s up to 10-
fold. Synergistic drug interactions were obtained in sequential combination of chlorpromazine 
or quinacrine with i) everolimus (an immunosuppressant agent that inhibits cholesterol 
esterification by an as yet unknown mechanism) [22,23]; ii) pioglitazone (an anti-diabetic 
drug that induces cell redistribution of free fatty acids) [24]; iii) verapamil (a calcium-25 
blocking drug that inhibits cholesterol trafficking from the plasma membrane to the 
endoplasmic reticulum) [21, refs therein]; and iv) progesterone (a sterol hormone that affects 
cholesterol trafficking from both the plasma membrane and lysosomes) [25,26]. 
Chlorpromazine and quinacrine are known to inhibit prion in vitro and to some extent also in 
vivo [2,27]. Although the exact mechanism(s) remains to be established, these drugs have 30 
been involved in: i) competitive inhibition of endogenous sulfated glycosaminoglycans 
(GAGs)-PrP interaction, essential for PrP
res
 formation or stabilization in the endosomes; ii) 
unfolding of PrP
res
 by drug-induced endosome/lysosome accumulation of chaperone-like 
factor(s); iii) destabilization of PrP
res
 by alteration of lysosomal pH [12]. Recent evidence, 
however, not formally excluding the above mechanisms, indicates that quinacrine and 35 
chlorpromazine might exert anti-prion effect by additional mechanisms that involve 
interference with intracellular cholesterol. Quinacrine has been reported to determine 
destabilization of cholesterol-rich membrane domains (DRMs or rafts) [28]. Worthy of note, 
these Authors also described a synergistic anti-prion effect of quinacrine in combination with 
simvastatin, a known inhibitor of cholesterol biosynthesis, and the anti-prion activity of 40 
progesterone. As for chlorpromazine, a study on the role of cellular cholesterol in the 
pathogenesis of schizophrenia, indicated that drug-induced transcriptional activation of 
cholesterol biosynthesis could represent a novel mechanism of action for some antipsychotic 
drugs, chlorpromazine being one of the most potent [29]. Hence, observed anti-PrP
res
 
synergistic effects may arise from the interaction of drugs affecting cellular cholesterol 45 
metabolism at different levels. Although suffering from quantitative discrepancies, probably 
due to the different detection sensitivities of the various techniques used, the results obtained 
in the 22L-infected N2a cells by ORO, Nile red, and filipin staining, as well as by enzymatic 
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and chemical methods, clearly indicate a derangement of type and distribution of intracellular 
lipids, possibly at the expense of plasma membrane functional integrity. Compared to N2a, 
22L-infected N2a cells displayed significant higher content and neosynthesis of FC, CE, and 
TG, coupled with no variation in cholesterol efflux; the CE sub-fraction appearing the most 
altered. These results are in agreement with a number of previous studies on mouse brains 5 
during the course of prion infection, showing altered cholesterol metabolism/esterification 
with an over-expression of the enzyme responsible for intracellular cholesterol esterification, 
ACAT1 (soat1) [30, refs therein]. Altered cholesterol homeostasis may affect functional 
integrity of membrane lipid domains leading to altered clustering process of raft-resident 
proteins and to increased conversion of PrP
C
 into the misfolded isoform [31]. The ability of 10 
combined treatments of everolimus and chloropromazine, or everolimus and quinacrine, to 
restore intracellular content and distribution of PL, NL, and FC similar to uninfected-
untreated N2a cells supports this hypothesis and may account for the enhanced anti-prion 
effect of these drug combinations. On the other hand, a mechanism involving inhibition of the 
drug-efflux pump P-gp seems unlikely. Firstly, most synergistic effects against PrP
res
 were 15 
obtained with P-gp inhibitors (progesterone and verapamil) at concentrations 4/5-fold lower 
than those required to increase vinblastine influx. Secondly, everolimus, at the highest 
concentration tested (i.e. 1 µM) increased vinblastine retention by only 10%. Worthy of note, 
a recent study by Bate et al. reported a higher toxicity of some ACAT inhibitors (i.e. TMP-
153, FR179254 and YIC-C8-434) in prion-infected ScGT1 and ScN2a cell lines vs. 20 
uninfected cells [32]. However, none of the CE modulators used in the present study affected 
the viability of 22L-infected and uninfected N2a cells, neither in single nor in combinatory 
drug experiments.  
Taken together these results indicate that inhibition of prion replication can be readily 
potentiated by combinatorial drug treatments and that steps of cholesterol/cholesterol ester 25 
metabolism may represent suitable targets. Indeed, in prion-infected N2a cells, that clearly 
displayed altered lipid homeostasis, the combined treatments with CE modulators associated 
with cholesterol metabolism interfering anti-prion drugs, appear to re-establish the 
intracellular lipid profile of untreated-uninfected cells.  
Some findings in this study have been the subject of patent applications PCT/IT2007/000109 30 
(Methods for the therapy of proliferative and/or conformational diseases) and 
PCT/IT2007/000110 (Methods for the diagnosis of proliferative and/or conformational 
diseases), inventors S. Dessì, P. La Colla, and A. Pani. 
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Table 1. Cytotoxicity of single vs. dual drug treatments in 22L-infected N2a cells. 
Values represent the mean ±SD of duplicate samples from three independent experiments.  
 
  DX 500  µM CC50 CP µM CC50 Q µM CC50 
  1x 
10-15 
5 
x10-16 
2.4 
x10-16 
1.2 
x10-16 
1 
x10-16 
10 5 2.5 1.25 98±11 1 0.5 0.25 0.12 4.5±1.3 
 CC50 Mean cell viability   (% of controls) 
EVE µM 1.2±.2                
 0.5  100±2 100±2 100±2 100±2  98±3 100±2 100±2 100±2  93±2 98±1 100±2 100±2  
0.25  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  94±1 100±2 100±2 100±2  
0.12  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  
0.06  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  
  Mean cell viability   (% of controls) 
PIO µM 53±4.1                
 40  75±2 74±1 75±3 73±1  96±3 92±3 92±3 94±1  79±4 80±3 78±3 79±2  
20  84±2 83±3 80±2 83±1  100±2 100±2 100±2 100±2  90±3 94±2 95±2 99±1  
10  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  94± 100±2 100±2 100±2  
5  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  
  Mean cell viability   (% of controls) 
VP µM 97±8.7                
10  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  89±3 100±2 100±2 100±2  
5  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  93±3 100±2 100±2 100±2  
2.5  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  93±2 100±2 100±2 100±2  
1.25  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  
  Mean cell viability   (% of controls) 
PG µM 135±8.8                
30  100±2 100±2 100±2 100±2  69±5 82±2 89±1 99±3  90±3 95±1 100±2 100±2  
15  100±2 100±2 100±2 100±2  90±3 98±1 100±2 100±2  93±2 99±1 100±2 100±2  
7.5  100±2 100±2 100±2 100±2  97±3 100±2 100±2 100±2  92±1 100±2 100±2 100±2  
3.75  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  100±2 100±2 100±2 100±2  
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Table 2. MDR1/P-gp drug efflux activity in 22L-infected N2a cell lines. 
[
3
H]-VBL 
CPM/µg protein ± SD 
 
 
Drug 
 
 
[µM] 1 hour 96 hours 
 
No drug 
 
- 
 
28.11±3.3 
 
36.30±2.2 
35 37.28±3.1 41.85±2.2   
15 32.18±2.5 36.10±1.6   
 
Progesterone 
    7.5 28.43±2.9 36.32±2.5  
10 60.68±4.2 63.79±3.9  
  5 45.77±3.3 39.21±3.6   
 
Verapamil 
     2.5 28.34±1.7 36.06±1.0   
 1 30.59±1.9 35.85±2.4   
    0.5 28.32±2.1 33.63±2.2   
 
Everolimus 
      0.05 28.04±2.8  34.87± 1.7  
40 30.39± 2.2 50.73±3.8   
20 28.65±3.1 37.33±3.3   
 
Pioglitazone 
10 28.88±2.0 36.73±1.1  
Values represent the mean ±SD of triplicate determinations from three  
independent experiments.  
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Figure 1.  
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Figure 1. Anti-prion activity of tannic acid and DX500 in combination with everolimus 
and progesterone. Prion-infected 22L-N2a cells were pre-treated for 8 hours with different concentrations 
of everolimus or progesterone prior to the addition of different concentrations of tannic acid or DX500. After 96 5 
hours, cells were lysed and processed for detection of PrP
res
 by dot blot with mouse monoclonal 6H4 antibody 
(Prionics). A) Isoboles and FIC indices of drug combinations. B) Representative dot blots of anti-prion effects of 
everolimus (EVE) and DX500, alone and in combination. Controls (C A-D). DX500 alone: 0.5 µg/ml (A1); 0.25 
µg/ml (B1), 0.125 µg/ml (C1); 0.06 µg/ml (D1). EVE alone: 0.5 µM (A6); 0.25 µM (B6); 0.125 µM (C6), 0.06 
µM (D6). EVE 0.5 µM (A-D2) with DX500 0.5 µg/ml (A2); DX5000.25 µg/ml (B2), DX500 0.125 µg/ml (C2); 10 
DX500 0.06 µg/ml (D2). EVE 0.25 µM (A-D3) with DX500 0.5 µg/ml (A3); DX5000.25 µg/ml (B3), DX500 
0.125 µg/ml (C3); DX500 0.06 µg/ml (D3). EVE 0.125 µM (A-D4) with DX500 0.5 µg/ml (A4); DX500 0.25 
µg/ml (B4), DX500 0.125 µg/ml (C4); DX500 0.06 µg/ml (D4). EVE 0.06 µM (A-D5) with DX500 0.5 µg/ml 
(A5); DX5000.25 µg/ml (B5), DX500 0.125 µg/ml (C5); DX500 0.06 µg/ml (D5). 
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Figure 2. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
1   2 3 4 5 6
A
B
C
D
C Everol imusChlorproma zine
Chlorpromazine+ Everolimus
 
 
0
2
4
6
8
10
0 2 4 6 8 10
Chlorpromazine [µM]
V
e
ra
p
a
m
il
[µ
M
]
0,42
0,47
0
5
10
15
20
25
30
35
0 2 4 6 8 10
Chlorpromazine [µM]
P
ro
g
e
s
te
ro
n
e
 [
µ
M
]
0,61
0,33
0,23
0
0,2
0,4
0,6
0,8
1
0 2 4 6 8 10
Chlorpromazine [µM]
E
v
e
ro
li
m
u
s
[µ
M
]
0,39
0,25
0,21
0
10
20
30
40
0 2 4 6 8 10
Chlorpromazine [µM]
P
io
g
li
ta
z
o
n
e
[µ
M
]
0,73
0,39
0,25
V
e
ra
p
a
m
il
[µ
M
]
V
e
ra
p
a
m
il
[µ
M
]
P
ro
g
e
s
te
ro
n
e
 [
µ
M
]
P
ro
g
e
s
te
ro
n
e
 [
µ
M
]
E
v
e
ro
li
m
u
s
[µ
M
]
E
v
e
ro
li
m
u
s
[µ
M
]
P
io
g
li
ta
z
o
n
e
[µ
M
]
P
io
g
li
ta
z
o
n
e
[µ
M
]
 
Figure 2. Anti-prion activity of chlorpromazine in combinations with everolimus, 
pioglitazone, progesterone, and verapamil. Prion-infected 22L-N2a cells were treated for 8 hours 
with different concentrations of everolimus, pioglitazone, progesterone, and verapamil prior to the addition of 
different concentrations of chlorpromazine. After 96 hours cells were lysed and processed for detection of PrP
res
 5 
by dot blot with mouse monoclonal 6H4 (Prionics). A) Isoboles and FIC indices of combinations. B) A 
representative dot blot of the anti-prion effect of everolimus (EVE) and chlorpromazine (CP), alone and in 
combination. Controls (C A-D). CP alone: 10 µM (A1); 5 µM (B1); 2.5 µM (C1) and 1.25 µM (D1). EVE alone: 
0.5 µM (A6); 0.25 µM (B6); 0.125 µM (C6), 0.06 µM (D6). EVE 0.5 µM (A-D2) with CP 10 µM (A2); CP 5 
µM (B2), CP 2.5 µM (C2); CP 1.25 µM (D2). EVE 0.25 µM (A-D3) with CP 10 µM (A3); CP 5 µM (B3), CP 10 
2.5 µM (C3); CP 1.25 µM (D3). EVE 0.125 µM (A-D4) with CP 10 µM (A4); CP 5 µM (B4), CP 2.5 µM (C4); 
CP 1.25 µM (D4). EVE 0.06 µM (A-D5) with CP 10 µM (A5); CP 5 µM (B5), CP 2.5 µM (C5); CP 1.25 µM 
(D5). 
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Figure 3. 
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Figure 3. Anti-prion activity of quinacrine in combination with everolimus, pioglitazone, 
progesterone and verapamil. Prion-infected 22L-N2a cells were treated with different concentrations of 
everolimus, pioglitazone, progesterone and verapamil for 8 hours prior to the addition of different concentrations 5 
of quinacrine. After 96 hours, cells were lysed and processed for detection of PrP
res
 by dot blot with mouse 
monoclonal 6H4 (Prionics). A) Isoboles and FIC indices of combinations. B) A representative dot blot of the 
anti-prion effect of everolimus (EVE) and quinacrine (Q), alone and in combination. Controls (C A-D). Q alone: 
1 µM (A1); 0.5 µM (B1); 0.25 µM (C1) and 0.12 µM (D1). EVE alone: 0.5 µM (A6); 0.25 µM (B6); 0.125 µM 
(C6), 0.06 µM (D6). EVE 0.5 µM (A-D2) with Q 1 µM (A2); Q 0.5 µM (B2), Q 0.25 µM (C2); Q 0.12 µM (D2). 10 
EVE 0.25 µM (A-D3) with Q 1 µM (A3); Q 0.5 µM (B3), Q 0.25 µM (C3); Q 0.12 µM (D3). EVE 0.125 µM 
(A-D4) with Q 1 µM (A4); Q 0.5 µM (B4), Q 0.25 µM (C4); Q 0.12 µM (D4). EVE 0.06 µM (A-D5) with Q 1 
µM (A5); Q 0.5 µM (B5), Q 0.25 µM (C5); Q 0.12 µM (D5). 
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Figure 4.  
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Figure 4. Oil red O staining of 22L-infected N2a cells after single and dual drug 
treatments. 22L-infected cells were incubated in the absence or in the presence of everolimus (EVE, 0.02µM) 
and chlorpromazine (CP, 2µM), alone or in combination. Control uninfected N2a cells were incubated in drug-
free medium. After 96 hours, cell cultures were processed for evaluation of neutral lipid-bound oil red O. (A) 5 
Representative microscopic visualization of neutral lipid accumulation. (B) Quantitative measurements of oil red 
O staining. Data are expressed as mean pixel values /cm
2
 of six created ROIs (Regions Of Interest) ±SE. 
*p<0.05, 22L-infected N2a cells vs. N2a cells; **p<0.05, treated vs. untreated 22L-infected N2a cells.  
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Figure 5. Nile red and filipin staining of 22L-infected N2a cells after single and dual 
drug treatments. 22L-infected cells were incubated in the absence or in the presence of everolimus (EVE, 
0.02µM) and chlorpromazine (CP, 2µM), alone or in combination. Control uninfected N2a cells were incubated 
in drug-free medium. After 96 hours, cell cultures were stained with Nile red and filipin. (A) Representative 
microscopic visualization of stained cultures.  NR-590 and NR-535 represent the red and green Nile red 15 
emissions which distinguish low-hydrophobic (i.e., phospholipids) and high-hydrophobic (i.e., triglycerides and 
cholesterol ester) lipids, respectively. Filipin stains free cholesterol. The three pictures are merged in the colour 
picture. Note that the white color, prevalent in 22L-infected cultures, is given by the overlay of the three signals. 
B) Quantitative analysis of Nile red and filipin staining. Data are the mean ± SD of the fluorescence intensity of 
NR-590, NR-535 and filipin staining. *p<0.05, 22L-infected N2a cells vs. N2a cells; °p<0.05, treated vs. 20 
untreated 22L-infected N2a cells.  
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Figure 6 
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Figure 6. N2a vs. 22L-N2a lipid content by TLC. TL were extracted with cold acetone from 
triplicate N2a and 22L-N2a cell cultures. A total of 30x10
6 
of each cell culture was collected from sub-confluent 
flasks. Extracted lipids were split into two equal aliquots and air dried: one aliquot was used to determine TC by 
the cholesterol oxidase method; the other aliquot, after drying, was resuspended in 100 µl of chloroform and 5 
analysed for lipid subclasses by TLC on kiesegel plates as described in the Methods section. A) TLC separated 
bands as visualized by iodine vapor. B) TC, FC, CE and TG as determined by enzymatic methods. Data are the 
mean ± SE of triplicate cultures, *p<0.05, 22L-infected N2a cells vs. N2a cells; **p<0.05, treated vs. untreated 
22L-infected N2a cells.  
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Figure 7. Effect of single vs. dual drug combinations on lipid synthesis and efflux. N2a 
and 22L-N2a
 
cells were seeded at 1x10
4
/ml in flat-bottom 24-well plates. After overnight 
settlement, a set of 22L-N2a
 
cultures were drug-treated (EVE, 0.02 µM; CP, 2 µM; Q, 0.2 
µM) and further incubated for 72 hours. Cellular lipid syntheses (TC, FC, CE, TG) were 15 
evaluated by incubating cells for 6 hours in medium containing 2 µCi/ml of [1-
14
C]acetate. 
After labeling, cells were washed with PBS and lipids extracted with cold acetone. Lipid 
subclasses were separated by thin layer chromatography (TLC) and [
14
C]acetate incorporation 
into the various lipid fractions was measured. Efflux from the cells into the medium was 
expressed as the percentage of radioactivity in medium/total
 
radioactivity (cells + medium). 20 
Each drug and drug combination was tested in triplicate. A) Total lipids and efflux; B) FC, 
CE, and TG. Data shown are the mean ± SE of triplicate cultures. *p<0.05, 22L-infected N2a 
cells vs. N2a cells; **p<0.05, treated vs. untreated 22L-infected N2a cells.  
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